Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide alone and in combination with sibutramine or phentermine in obesity
NCT00402077Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2006
- Primary completion
- Aug 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pramlintide in obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: All treatment-emergent adverse events at 24 weeks and Absolute change in body weight at 12 weeks. Started Nov 2006; status: completed.
02
Drugs
pramlintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00402077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402077.